PXS It's not FDA approval, it's orphan drug status
Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity. The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well‐controlled studies.
- Forums
- ASX - Day Trading
- Morning trading July 14
Morning trading July 14, page-336
-
- There are more pages in this discussion • 164 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)